Compare Cipla with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ASTRAZENECA PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ASTRAZENECA PHARMA CIPLA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 22.6 94.2 24.0% View Chart
P/BV x 2.5 26.5 9.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 CIPLA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-19
ASTRAZENECA PHARMA
Mar-18
CIPLA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6781,278 53.1%   
Low Rs484883 54.8%   
Sales per share (Unadj.) Rs198.2228.4 86.8%  
Earnings per share (Unadj.) Rs18.510.4 178.7%  
Cash flow per share (Unadj.) Rs35.016.3 215.2%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs186.398.8 188.6%  
Shares outstanding (eoy) m805.7025.00 3,222.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.94.7 62.0%   
Avg P/E ratio x31.4104.2 30.1%  
P/CF ratio (eoy) x16.666.4 25.0%  
Price / Book Value ratio x3.110.9 28.5%  
Dividend payout %16.20-   
Avg Mkt Cap Rs m468,03127,008 1,733.0%   
No. of employees `00022.61.4 1,669.9%   
Total wages/salary Rs m28,5651,535 1,860.6%   
Avg. sales/employee Rs Th7,053.14,210.9 167.5%   
Avg. wages/employee Rs Th1,261.51,132.2 111.4%   
Avg. net profit/employee Rs Th659.1191.1 344.9%   
INCOME DATA
Net Sales Rs m159,7105,710 2,797.0%  
Other income Rs m4,766123 3,890.4%   
Total revenues Rs m164,4755,833 2,820.0%   
Gross profit Rs m30,973463 6,691.1%  
Depreciation Rs m13,263147 8,998.0%   
Interest Rs m1,6840-   
Profit before tax Rs m20,791438 4,746.9%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,695179 3,183.5%   
Profit after tax Rs m14,924259 5,760.1%  
Gross profit margin %19.48.1 239.2%  
Effective tax rate %27.440.8 67.1%   
Net profit margin %9.34.5 205.9%  
BALANCE SHEET DATA
Current assets Rs m124,2663,209 3,872.2%   
Current liabilities Rs m37,7152,070 1,822.4%   
Net working cap to sales %54.220.0 271.5%  
Current ratio x3.31.6 212.5%  
Inventory Days Days9172 125.3%  
Debtors Days Days9535 271.6%  
Net fixed assets Rs m105,190790 13,310.2%   
Share capital Rs m1,61150 3,222.8%   
"Free" reserves Rs m148,5112,419 6,138.6%   
Net worth Rs m150,1232,469 6,079.6%   
Long term debt Rs m38,3010-   
Total assets Rs m239,6334,605 5,203.3%  
Interest coverage x13.3NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.2 53.8%   
Return on assets %6.95.6 123.2%  
Return on equity %9.910.5 94.7%  
Return on capital %11.817.7 66.7%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,410300 19,165.2%   
Fx outflow Rs m19,0412,015 945.0%   
Net fx Rs m38,368-1,715 -2,236.7%   
CASH FLOW
From Operations Rs m16,91188 19,239.4%  
From Investments Rs m-16,687-94 17,827.8%  
From Financial Activity Rs m-3,487NA-  
Net Cashflow Rs m-3,451-6 60,545.6%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 0.3 4,066.7%  
FIIs % 23.7 15.7 151.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 9.1 287.9%  
Shareholders   161,166 12,856 1,253.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   TTK HEALTHCARE  ALEMBIC LTD  DR. REDDYS LAB  ELDER PHARMA  UNICHEM LAB  

Compare CIPLA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Nov 15, 2019 (Close)

TRACK CIPLA

CIPLA - TORRENT PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS